Maor I, Mandel H, Aviram M
Lipid Research Laboratory, Rambam Medical Center, Haifa, Israel.
Arterioscler Thromb Vasc Biol. 1995 Sep;15(9):1378-87. doi: 10.1161/01.atv.15.9.1378.
Macrophage uptake of oxidatively modified LDL (Ox-LDL), unlike the uptake of acetylated LDL (Ac-LDL), resulted in lysosomal accumulation of unesterified cholesterol (UC). As sphingomyelin (SM) binds UC with high affinity, we considered whether lysosomes also accumulate Ox-LDL-derived SM, and if such a phenomenon could be involved in the lysosomal trapping of Ox-LDL-derived UC. Incubation of J-774 A.1 macrophages with Ox-LDL increased the lysosomal accumulations of UC by 75% and SM by 63% compared with the effect of Ac-LDL. The addition of chlorpromazine, an inhibitor of lysosomal sphingomyelinase (SMase), to macrophages that were incubated with [3H]cholesteryl ester-labeled Ac-LDL also led to lysosomal accumulation of both SM and UC. 7-Ketocholesterol (7-KC), the major oxysterol in Ox-LDL, inhibited lysosomal SMase in a cell-free system. The addition of 7-KC to cells in the presence of [3H]choline- or [3H]cholesteryl ester-labeled Ac-LDL led to macrophage accumulation of SM or UC, respectively. Niemann-Pick type C disease (NP-C) is an inherited cholesterol-storage disease in which lysosomal SMase activity is attenuated after uptake of LDL. Incubation of monocyte-derived macrophages from two NP-C patients with Ac-LDL or Ox-LDL resulted in an accumulation of UC in the lysosomes, whereas normal monocyte-derived macrophages accumulate UC in their lysosomes after incubation with Ox-LDL but not Ac-LDL. These results suggest that inhibition of lysosomal SMase in NP-C cells or by 7-KC is required for lysosomal accumulation of UC. Analysis of the macrophage lysosomal extract (following cell incubation with Ox-LDL) by density-gradient ultracentrifugation and gel-filtration chromatography revealed the presence of a particle consisting of UC, SM, 7-KC, and apoB-100. We conclude that 7-KC in Ox-LDL can inhibit lysosomal SMase, thus leading to the accumulation of SM, which binds UC avidly and inhibits its further cellular processing out of the lysosome. As UC-SM particles of lysosomal origin exist in the atherosclerotic lesion, the formation of such particles may result from an impaired processing of Ox-LDL by arterial wall macrophages during early atherogenesis.
与巨噬细胞摄取乙酰化低密度脂蛋白(Ac-LDL)不同,其摄取氧化修饰的低密度脂蛋白(Ox-LDL)会导致溶酶体中未酯化胆固醇(UC)的积累。由于鞘磷脂(SM)能与UC高亲和力结合,我们考虑溶酶体是否也会积累Ox-LDL衍生的SM,以及这种现象是否与Ox-LDL衍生的UC在溶酶体中的滞留有关。与Ac-LDL的作用相比,用Ox-LDL孵育J-774 A.1巨噬细胞可使UC在溶酶体中的积累增加75%,使SM增加63%。向用[³H]胆固醇酯标记的Ac-LDL孵育的巨噬细胞中添加溶酶体鞘磷脂酶(SMase)抑制剂氯丙嗪,也会导致SM和UC在溶酶体中的积累。7-酮胆固醇(7-KC)是Ox-LDL中的主要氧化甾醇,在无细胞体系中可抑制溶酶体SMase。在存在[³H]胆碱或[³H]胆固醇酯标记的Ac-LDL的情况下,向细胞中添加7-KC分别导致巨噬细胞中SM或UC的积累。尼曼-匹克C型病(NP-C)是一种遗传性胆固醇储存疾病,其中低密度脂蛋白摄取后溶酶体SMase活性减弱。用Ac-LDL或Ox-LDL孵育两名NP-C患者的单核细胞衍生巨噬细胞会导致溶酶体中UC的积累,而正常单核细胞衍生巨噬细胞在用Ox-LDL而非Ac-LDL孵育后会在其溶酶体中积累UC。这些结果表明,NP-C细胞中或7-KC对溶酶体SMase的抑制是UC在溶酶体中积累所必需的。通过密度梯度超速离心和凝胶过滤色谱法分析巨噬细胞溶酶体提取物(在用Ox-LDL孵育细胞后),发现存在一种由UC、SM、7-KC和载脂蛋白B-100组成的颗粒。我们得出结论,Ox-LDL中的7-KC可抑制溶酶体SMase,从而导致SM的积累,SM能与UC紧密结合并抑制其从溶酶体中进一步进行细胞处理。由于溶酶体来源的UC-SM颗粒存在于动脉粥样硬化病变中,这种颗粒的形成可能是由于动脉壁巨噬细胞在早期动脉粥样硬化形成过程中对Ox-LDL的处理受损所致。